Impact Factor 4.716 | CiteScore 4.71
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.02014

Interleukin-1 family cytokines: keystones in liver inflammatory diseases

 Louise Barbier1, 2,  Maroua Ferhat1, Ephrem Salame1, 2, Aurélie Robin1,  Andre Herbelin1*, Jean-Marc Gombert1, 3, Christine Silvain3 and  Alice Barbarin1
  • 1Institut National de la Santé et de la Recherche Médicale (INSERM), France
  • 2Centre Hospitalier Universitaire de Tours, France
  • 3Centre Hospitalier Universitaire (CHU) de Poitiers, France

The pyrogenic property being the first activity described, members of the interleukin-1 superfamily (IL-1α, IL-1β, IL-18, and the newest members: IL-33, IL-36, IL-37, and IL-38) are now known to be involved in several inflammatory diseases such as obesity, atherosclerosis, cancer, viral and parasite infections, and auto-inflammatory syndromes as well as liver diseases. Inflammation processes are keystones of chronic liver diseases, of which the etiology may be viral or toxic, as in alcoholic or non-alcoholic liver diseases. Inflammation is also at stake in acute liver failure involving massive necrosis, and in ischemia-reperfusion injury in the setting of liver transplantation. The role of the IL-1 superfamily of cytokines and receptors in liver diseases can be either protective or pro-inflammatory, depending on timing and the environment.
Our review provides an overview of current understanding of the IL-1 family members in liver inflammation, highlighting recent key investigations and therapeutic perspectives.
We have tried to apply the concept of trained immunity to liver diseases, based on the role of the members of the IL-1 superfamily, first of all IL-1β but also IL-18 and IL-33, in modulating innate lymphoid immunity carried by natural killer cells, innate lymphoid cells or innate T-αβ lymphocytes.

Keywords: Interleukin-1, interleukin-33, Interleukin-37, Inflammation, Liver Diseases, alcoholic liver disease ALD, Non-alcoholic liver disease (NAFLD), trained immunity, innate immunity, invariant natural killer T-cell, Natural Killer cell, hepatoce

Received: 07 Mar 2019; Accepted: 08 Aug 2019.

Edited by:

Elizabeth Brint, University College Cork, Ireland

Reviewed by:

Aldo Tagliabue, Institute for Genetic and Biomedical Research (IRGB), Italy
Parameswaran Ramakrishnan, Case Western Reserve University, United States  

Copyright: © 2019 Barbier, Ferhat, Salame, Robin, Herbelin, Gombert, Silvain and Barbarin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Andre Herbelin, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, 75654, Île-de-France, France, andre.herbelin@inserm.fr